2022 Compound Screening Trials 
Drug Discovery World
OCTOBER 4, 2022
Using its proprietary compound screening platform, Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are easy to administer and cost-effective. . million in 2022 to 12.7 Volume 23 – Issue 4, Fall 2022. With its recent award of $3.35 million by 2050.” .
Drug Discovery World
JANUARY 26, 2023
The Market After over two years of the Covid-19 pandemic, 2022 year was somewhat of a return to normal for both the world at large and the pharmaceutical industry. As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities. However, that is not to say it was an easy year.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JANUARY 23, 2023
Clinical trials revealed eight out of nine predictions were correct. Today, there have been efficacy readouts from large randomised controlled clinical trials for nine of our predictions – eight of which we predicted correctly. Results from Recursion’s Covid-19 efficacy predictions following clinilcal trial readouts.
Broad Institute
JULY 26, 2022
Resources, services, and tools By Maria Nemchuk July 26, 2022 Breadcrumb Home Resources, services, and tools Key scientific datasets and computational tools developed by our scientists and their collaborators. Learn more PRISM Rapid, high-throughput multiplexed compound screening in genomically characterized human cancer cell-line models.
Drug Discovery World
AUGUST 15, 2023
Consequently, electrophysiological techniques need to be developed that can provide better translation from small mammalian hearts into larger hearts and then on into human clinical trials. 2022) Nature Reviews Drug Discovery, 21: 915–931. DDW Volume 24 – Issue 3, Summer 2023 References Scannell et al. Scannell & Bosley.
Expert insights. Personalized for you.
130 
Let's personalize your content